June 28, 2012
WASHINGTON – Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (ASBM) issued the following statement in response to the Supreme Court ruling on the Affordable Care Act and its impact on the Food and Drug Administration’s (FDA) creation of a biosimilar pathway. “As biosimilar medicines are introduced into the U.S. in the […]
June 18, 2012
ASBM Chairman Dr. Richard Dolinar convened a working group of Advisory Board members to discuss the elements of a physician notification policy for biosimilars that prioritizes patient safety. Read the summary.
June 18, 2012
ASBM Chairman Dr. Richard Dolinar convened a working group of Advisory Board members to discuss the elements of a physician notification policy for biosimilars that prioritizes patient safety. Read the summary.
November 4, 2011
By Bruce Rubin MedPage Today Although politicians and patients may debate the benefits and drawbacks of the U.S. healthcare system, when it comes to inventing new medical technologies and discovering life-saving treatments, no other nation matches the U.S. in terms of innovation and delivery of care. One reason the U.S. is so successful is that […]
October 5, 2011
By Kathy Feegal Dr. Richard Dolinar, the Alliance’s chairman, was a keynote speaker at a biosimilars roundtable discussion in Boston, MA on October 5, 2011. The event was hosted by Northeastern University and was attended by numerous stakeholders from across New England, including the Massachusetts Medical Society, and patients groups such as the National Kidney […]
September 28, 2011
The Alliance for Safe Biologic Medicines joined with the Virginia Biotechnology Association at an event to expore with patients, advocates, physicians and other healthcare providers the importance of maintaining patient safety as the U.S. FDA’s top priority while it works to establish a pathway for approval for biosimilar products.
August 4, 2011
Developing the Nation’s Biosimilars Program Steven Kozlowski, M.D., Janet Woodcock, M.D., Karen Midthun, M.D., and Rachel Behrman Sherman, M.D., M.P.H. New England Journal of Medicine August 4, 2011 Biologic products developed over the past three decades and approved by the Food and Drug Administration (FDA) now provide important therapeutic options for a variety of serious […]
July 13, 2011
BioFlorida BioFlorida Institute Florida BioDatabase Florida Bioscience Education and Training Resources Florida Biotechnology News Florida Department of Health Florida House of Representatives Florida Institute of Technology Florida Medical Association Florida State Legislature Florida State Senate Office of Governor Rick Scott
July 13, 2011
BioFlorida BioFlorida Institute Florida BioDatabase Florida Bioscience Education and Training Resources Florida Biotechnology News Florida Department of Health Florida House of Representatives Florida Institute of Technology Florida Medical Association Florida State Legislature Florida State Senate Office of Governor Rick Scott
June 17, 2011
BaltimoreBio Biotechnical Institute of Maryland, Inc. Greater Baltimore Tech Council Johns Hopkins University Technology Transfer Maryland Biotechnology Center Maryland Department of Labor, Licensing and Regulation Maryland Department of Health and Mental Hygiene Maryland General Assembly Maryland Life Sciences Advisory Board Maryland Technology Enterprise Institute Office of Governor Martin O’Malley Tech Council of Maryland
